8-K: Interpace Biosciences Q2: Thyroid Growth Amid Pivot

Interpace Biosciences reports a 23% revenue decrease in Q2 2025 due to PancraGEN wind-down, but sees record thyroid test volume and revenue growth.

Summary

• Net Revenue for Q2 2025 was $9.2 million, a 23% decrease from $12.0 million in Q2 2024.
• The company reported a loss from continuing operations of $0.5 million in Q2 2025, compared to an income of $2.5 million in Q2 2024.
• Q2 2025 results include $1.2 million in one-time charges related to the wind-down of PancraGEN testing.
• Thyroid test volume increased by 16% year-over-year, reaching record levels.
• Thyroid revenue reached a record $8.7 million in Q2 2025, up 25% year-over-year.
• Cash collections for Q2 2025 totaled $10.8 million, slightly down from $11.0 million in Q2 2024.
• Gross Profit percentage was 57% in Q2 2025, down from 65% in Q2 2024, but would have been 65% without the one-time PancraGEN impact.
• Adjusted EBITDA was $0.4 million in Q2 2025, a significant decrease from $2.8 million in Q2 2024.
• Preliminary revenue for July 2025 was $3.3 million, a 54% increase compared to July 2024.

Sentiment

Score: 6

Explanation: While overall financial metrics for Q2 2025 show a significant decline due to the PancraGEN wind-down and associated one-time charges, the company's core thyroid testing business demonstrated strong growth in volume (16%) and revenue (25%). Management's commentary indicates a successful strategic pivot and positive momentum continuing into Q3, suggesting a challenging but well-managed transition towards a more focused and potentially profitable business model.

Positives

• Achieved record Thyroid test volume, up 16% year-over-year.
• Thyroid revenue reached record levels at $8.7 million, up 25% year-over-year.
• Strong cash position enabled strategic investments in lab operational efficiency, AI, and automation digital strategy.
• Strengthened the balance sheet through additional principal payments on long-term debt.
• Positive trends observed in Q2 have continued into Q3, with preliminary July 2025 revenue up 54% year-over-year to $3.3 million.
• Successfully transitioning to a thyroid-only clinical diagnostics business, which is expected to be more adequately reflected in Q3 and beyond.

Negatives

• Net Revenue decreased by 23% to $9.2 million in Q2 2025 compared to $12.0 million in Q2 2024.
• Reported a loss from continuing operations of $0.5 million in Q2 2025, a decline from an income of $2.5 million in Q2 2024.
• Operating loss was $0.5 million in Q2 2025, compared to an operating income of $2.6 million in Q2 2024.
• Adjusted EBITDA significantly decreased to $0.4 million in Q2 2025 from $2.8 million in Q2 2024.
• Gross Profit percentage declined to 57% in Q2 2025 from 65% in Q2 2024.
• Impacted by the loss of reimbursement for PancraGEN testing, leading to a strategic wind-down.
• Incurred $1.2 million in one-time charges associated with the PancraGEN wind-down.
• Cash and cash equivalents decreased from $1,461 thousand at December 31, 2024, to $502 thousand at June 30, 2025.

Risks

• Estimates of future revenue, cash flows, and adjusted EBITDA may prove materially inaccurate.
• Prior history of operating losses.
• Ability to adequately finance the business and seek alternative sources of financing.
• Ability to repay borrowings from BroadOak.
• Dependence on sales and reimbursements from clinical services.
• Ability to retain or secure reimbursement, including reliance on third parties to process and transmit claims to payers.
• Adverse impact of any delay, data loss, or other disruption in processing or transmitting claims.
• Revenue recognition being based in part on estimates for future collections, which estimates may prove to be incorrect.
• Ability to restructure the company in light of the loss of reimbursement for its PancraGEN product.

Future Outlook

The company anticipates continued growth in revenue, profitability, and cash flow as a thyroid-only clinical diagnostics business, with these improvements expected to be more adequately reflected in Q3 2025 and beyond. Preliminary revenue for July 2025 shows a substantial 54% increase compared to July 2024, indicating positive trends are continuing.

Management Comments

• Chris McCarthy, CFO: "Our second quarter results were impacted by the loss of reimbursement for our PancraGEN testing. The reported loss includes one-time charges of $1.2 million associated with the wind-down of PancraGEN as we complete our transition to a company focused on Thyroid testing."
• Chris McCarthy, CFO: "Our strong cash position enabled strategic investments in lab operational efficiency, leveraging our AI and automation digital strategy, and allowed us to further strengthen our balance sheet through additional principal payments on our long-term debt agreement. The positive trends seen in Q2 have continued into the third quarter. Preliminary revenue for July 2025 was $3.3 million, marking a substantial 54% increase compared to July 2024."
• Tom Burnell, President and CEO: "Despite the loss of reimbursement for the Companys PancraGEN test, Q2 2025 represented another quarter of year-overyear double digit Thyroid volume and revenue growth."
• Tom Burnell, President and CEO: "We are excited about the Companys continued growth in revenue, profitability and cash flow as a thyroid only clinical diagnostics business, which will be more adequately reflected in Q3 and beyond."
• Tom Burnell, President and CEO: "The strength and resiliency of the Interpace team, coupled with their ability to anticipate and prepare for change, has made for a smooth transition away from the unwarranted challenges as a result of loss of PancraGEN reimbursement to a thriving thyroid testing business."

Industry Context

Interpace Biosciences is undergoing a significant strategic pivot within the clinical diagnostics industry, shifting its focus entirely to thyroid testing. This move comes after the loss of reimbursement for its PancraGEN test, highlighting the challenges and regulatory pressures faced by diagnostic companies regarding reimbursement policies. The emphasis on AI and automation for lab efficiency reflects a broader industry trend towards leveraging technology to improve operational costs and diagnostic accuracy. The strong growth in the thyroid segment suggests a robust market for specialized molecular diagnostics in this area, potentially positioning Interpace as a niche leader.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards is not possible based solely on the provided information.

Stakeholder Impact

• Shareholders: Experience short-term financial decline due to strategic pivot, but potential for long-term growth in a focused thyroid diagnostics business.
• Customers: Those relying on PancraGEN will need to find alternative solutions; thyroid testing customers benefit from continued and growing service.
• Employees: Implied restructuring related to the PancraGEN wind-down may impact some employees, while the thyroid business continues to grow.
• Creditors: Positive impact due to additional principal payments on long-term debt, strengthening the balance sheet.

Next Steps

• Complete the transition to a company focused solely on Thyroid testing.
• Continue strategic investments in lab operational efficiency, AI, and automation digital strategy.
• Further strengthen the balance sheet through additional principal payments on long-term debt.
• Reflect continued growth in revenue, profitability, and cash flow as a thyroid-only business in Q3 2025 and beyond.

Key Dates

Recommendation

The company is undergoing a significant strategic transition, exiting the PancraGEN business due to reimbursement issues and focusing entirely on thyroid testing. While this resulted in a substantial decline in overall revenue, profit, and EBITDA for Q2 2025, the core thyroid business demonstrated strong double-digit growth in both volume and revenue, with positive trends continuing into Q3. The one-time charges associated with the wind-down are a temporary drag. For a seasoned investor, this presents a mixed picture: short-term financial weakness offset by a clear strategic direction and growth in the new core segment. A 'hold' recommendation is appropriate to observe the successful completion of this transition and the sustained profitability of the thyroid-only business in subsequent quarters before making a more definitive investment decision.

Keywords

Thyroid testing, Clinical diagnostics, Molecular diagnostics, Personalized medicine, PancraGEN, ThyGeNEXT, ThyraMIRv2, RespriDX, Barrett's Esophagus, Esophageal cancer, Biotechnology, Healthcare, SEC filing, Financial results